Home › Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma clinical trials recruiting in the U.S.
23 studies for Precursor T-Cell Lymphoblastic Leukemia-Lymphoma are recruiting participants at sites across the United States.
Cities with the most studies
- Houston, TX8 studies
- New York City, NY6 studies
- Washington, DC5 studies
- Columbus, OH5 studies
- St. Louis, MO4 studies
- Boston, MA3 studies
- Queens, NY3 studies
- Edison, NJ3 studies
- Staten Island, NY3 studies
- Atlanta, GA3 studies
- Philadelphia, PA3 studies
- East Norwalk, CT3 studies
- Baldwin Park, CA3 studies
- New Rochelle, NY3 studies
By state
- California5 studies
- Colorado3 studies
- Florida3 studies
- Georgia3 studies
- Maryland3 studies
- Massachusetts3 studies
- Missouri4 studies
- New Jersey3 studies
- New York7 studies
- North Carolina3 studies
- Ohio6 studies
- Pennsylvania4 studies
- Tennessee3 studies
- Texas8 studies
Recently updated studies
Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
RecruitingObservational studyHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT01087333Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT04301076Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma
RecruitingPhase 1
Ages 18 to 120 · All sexes · Updated Nov 9, 2026 · NCT07388563Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
RecruitingPhase 1
Ages 18 to 120 · All sexes · Updated Nov 2, 2026 · NCT06904066Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
RecruitingObservational study
Ages 18 to 120 · All sexes · Updated Oct 28, 2026 · NCT01137643Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 27, 2026 · NCT07356245Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients
RecruitingObservational study
Up to age 30 · All sexes · Updated Oct 9, 2026 · NCT07313592Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
RecruitingPhase 2
All ages · All sexes · Updated Oct 8, 2026 · NCT00501826A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
RecruitingPhase 2
6 Months · All sexes · Updated Sep 28, 2026 · NCT06514794A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)
RecruitingPhase 2
1 Month – 21 Years · All sexes · Updated Sep 18, 2026 · NCT06561074Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT05289687Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma
RecruitingPhase 1
Up to age 39 · All sexes · Updated Sep 11, 2026 · NCT04972942Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma
RecruitingPhase 1
Ages 12 to 30 · All sexes · Updated Aug 12, 2026 · NCT07513129Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
RecruitingPhase 2
Ages 1 to 18 · All sexes · Updated Aug 10, 2026 · NCT06390319Registry of Older Patients With Cancer
RecruitingObservational study
Ages 65 and older · All sexes · Updated Jun 29, 2026 · NCT01137825A Registry for People With T-cell Lymphoma
RecruitingObservational study
All ages · All sexes · Updated May 20, 2026 · NCT05978141CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)
RecruitingPhase 1
Up to age 21 · All sexes · Updated May 19, 2026 · NCT04318678Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car T Cells
RecruitingPhase 1
Up to age 75 · All sexes · Updated May 18, 2026 · NCT07220993Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Apr 14, 2026 · NCT05996185A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Mar 5, 2026 · NCT06698003Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 10, 2026 · NCT04848064Two Step Haplo With Radiation Conditioning
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 30, 2025 · NCT05031897Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 15, 2025 · NCT06462365From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.